| Trial ID: | L0886 |
| Source ID: | NCT01521494
|
| Associated Drug: |
Pa21
|
| Title: |
PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01521494/results
|
| Conditions: |
Chronic Kidney Disease Requiring Hemodialysis
|
| Interventions: |
DRUG: PA21|DRUG: PA21|DRUG: PA21|DRUG: PA21|DRUG: Placebo
|
| Outcome Measures: |
Primary: Change From Baseline in Serum Phosphorus Concentrations at the End of Treatment., Changes in serum phosphorus concentrations from baseline to the end of treatment were adjusted by serum phosphorus concentration at baseline., 6 weeks | Secondary: Change From Baseline in Serum Calcium Concentrations., 6 weeks|Change From Baseline in Serum Intact-PTH Concentrations., 6 weeks
|
| Sponsor/Collaborators: |
Sponsor: Kissei Pharmaceutical Co., Ltd.
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
183
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2012-01-11
|
| Completion Date: |
2012-07-03
|
| Results First Posted: |
2018-08-23
|
| Last Update Posted: |
2018-08-23
|
| Locations: |
Japan, Multiple Locations, Japan
|
| URL: |
https://clinicaltrials.gov/show/NCT01521494
|
